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Times They Are A-Changin
For several years we have had periodic updates to the percutaneous coronary intervention
(PCI) guidelines but now an entire new document, the first in 7 years, has been published and
I recommend it for your reading pleasure (1). But, just in case you have not digested all 47
text pages and referred to the 879 references listed, I thought that I might relay some of the
highlights. The evidence on which the guidelines are based continues to accumulate, and the
authors are justly proud that there are increasingly Levels of Evidence “A” and “B” (evidence-
based) and less “C” (imminence-based) recommendations. All iterations of the guidelines take
on a character of their own reflecting the spirit of the times. The earliest PCI (angioplasty)
guideline was only 2 pages and concentrated on gaining experience and the requirements for
surgical back-up. The American College of Cardiology/American Heart Association (ACC/
AHA) guidelines for PCI were published in 1988, 2003, and 2005, and updated in 2007 and
2009. That last one, because of a lot of overlap with the treatment of ST-segment elevation
myocardial infarction (STEMI), was a combined PCI and STEMI focused update to capture
the results of trials addressing issues pertinent to both.
The current guidelines, the 2011 American College of Cardiology Foundation/American
Heart Association/Society for Cardiac Angiography (ACCF/AHA/SCAI) guideline for PCI,
is not an update but a stand-alone, new guideline with its own characteristics driven by the
times we live in. In this guideline, the major emphasis is on appropriate selection for PCI and
coronary artery bypass grafting (CABG). There was extensive collaboration between the PCI
Writing Committee and the CABG Writing Committee, who penned their guidelines
concurrently along with the STEMI Committee and with consultation with the Stable
Ischemic Heart Disease Writing Committee. The most evident collaboration was with the
CABG writing group and this was reflected in the first subject addressed in this new
guideline. That section is titled, “Heart team approach to revascularization decisions.”
Although consultation between cardiologists and surgeons is a common practice in many
institutions, this “heart team” approach to decision-making is really borrowed from our
European colleagues who made it a centerpiece of their guidelines 2 years ago.
There are a number of other new things in the current guidelines including expanded
antiplatelet therapies (the addition of ticagrelor) and the change to firm recommendations for a
600-mg loading dose of clopidogrel and the reduction in chronic aspirin dose to 75 to 100 mg
per day. The STEMI section drops the “drip-and-ship” option for patients who cannot have
primary PCI and, therefore, receive thrombolysis. This version suggests waiting for signs of
failure to reperfuse before transfer. Those who have embraced “drip-and-ship” strategies will be
reassured that these are only guidelines. In addition, the paper contains sections on ethics,
statin use, hospitals without surgical back-up, radiation safety, and expanded recommendations
about anatomic subsets. But the overriding theme in this document is the heart team decision-
making process as it relates to selection for revascularization and for PCI versus CABG.
Although there are other studies cited for selection for PCI or CABG, the overriding evidence
comes from the SYNTAX (Synergy between Percutaneous Coronary Intervention with
TAXUS and Cardiac Surgery) trial (2) and substudies emanating from it. Careful reading of
the guideline is necessary, and by the way, easier, as the text has been abbreviated and tables
with specific recommendations have been inserted. The selection of PCI or CABG is divided
into “Recommendations to Improve Survival” and “Recommendations to Improve Symptoms”
compared to medical therapy. As far as clinical presentation is concerned, there is not much
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365new for STEMI, which is largely a primary PCI issue
when it is available, but for elective catheterization
patients, there are extensive recommendations. Many of
them reflect the 3-year findings of the SYNTAX trial so
that for survival, left main disease gets a Class I
recommendation for surgery and a Class IIa
recommendation for PCI when the SYNTAX score is
23 and the surgical risk is 5%. I guess CABG got the
nod here because of its seniority even though PCI beat
CABG in this SYNTAX category. If the SYNTAX score
was 34 and the survival risk was 2%, PCI got a Class
IIb recommendation (uncertain benefit). So, for left main
disease with low or intermediate SYNTAX scores and
close to usual surgical risk, PCI is a consideration
according the guidelines. Of course, surgery has been
compared to medical therapy for left main disease even if
the evidence is now almost historical. The catch-22 is
that PCI will not be compared to medical therapy for
these patients.
For improved survival or medical therapy in multivessel
disease patients, PCI gets only a Class IIb (of uncertain
benefit). CABG for survival benefit in 3-vessel disease
and 2-vessel disease with major ischemia gets a Class I
(3-vessel) and Class IIa (2-vessel). The best PCI can do
with the current evidence is a Class IIb (“the usefulness of
PCI to improve survival is uncertain with patients with 2-
or 3-vessel CAD”). The ISCHEMIA (International
Study of Comparative Health Effectiveness with Medical
and Invasive Approaches) trial and others comparing PCI
with medical therapy is sorely needed to provide the
evidence that PCI can improve survival in patients with
extensive ischemia.
The recommendations for symptom relief are more
balanced. For unacceptable angina despite guideline-
driven medical therapy and significant stenosis in 1 or
more arteries, both CABG and PCI get a Class I, Level
of Evidence: A recommendation. If medical therapy
produces adverse effects or the patient prefers
intervention, then for symptom relief a Class IIa is given
for CABG and PCI. Even for symptom relief, CABG isrecommended over PCI in 3-vessel disease patients with a
SYNTAX score 22.
We should remember that guidelines are guides, not
definitive rules. The consultation of interventionalists,
surgeons, and noninvasive cardiologists (the heart team) is a
concept that is hard to argue with. It is, however, one that is
hard to comply with. The widespread practice of ad-hoc
PCI at the time of diagnostic angiography leaves little time
for assembling the “heart team.” The guideline, however,
mirrors the European guideline in suggesting that for
patients with more extensive disease, a practice of taking the
patient off the catheterization table to allow for consultation
and informed consent is preferable. These recommendations
will be embraced by many but will be particularly hard for
the ever-expanding number of hospitals that have only PCI
available. A section on hospitals without in-house surgery is
included in the guideline.
Increasing scrutiny on appropriate decisions about
revascularization must encourage innovative ways to assure
that all therapeutic options are considered and patients
are informed. Future guideline updates should disseminate
those solutions that are effective and practical. As Dylan
said, “times they are a-changin’,” and guidelines are no
exception.
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